FDA Promises No More IND Disruptions Without “Very Valid Reasons,” Nears Agreement With NCI
In Brief: Recompetition Of Frederick Contract Flops, As Others Leave The Field To Litton-Bionetics
Search Committee Finishes Job, Submits Choices To Califano
New ACS Grants to Fund ‘Critical, Urgent’ Research
Sacharin Issue Splits Scientists; ACS Proposes Delaney Changes
UICC Announces Grant Programs to Continue
NCI Goofs On Contract Notice, Won’t Change Improper Deadline
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Johnson and Johnson reaches $5.5B settlement deal over talc lawsuits
- Pour a Scotch, we’re talking clinical trials and prediction markets
- FDA grants Replimune’s RP1 an accelerated approval on third submission after 10:3 vote from advisory committee
Amid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial - Consumers are increasingly accessing U.S. News rankings of cancer hospitals via AI chatbots
2026 report shows no change in the top-five lineup - The Directors: New directors Herbst and Gius chart a future built on AI, collaboration, and rural access









